ASC Durango (Colo.) recently underwent its first AAAHC survey and achieved accreditation. One of the areas the ASC was praised by surveyors for was its quality assessment and performance improvement ...

There are many risk factors for developing postoperative nausea and vomiting (PONV), but a simplified risk score can help with assessing those risk factors, said Jawad N. Saleh, PharmD, BSPharm, BCCCP ...

NEW ORLEANS -- There was no benefit to giving patients supplemental oxygen during surgery to reduce postoperative nausea and vomiting (PONV), according to a post hoc analysis of a randomized trial.

Dublin, Nov. 06, 2020 (GLOBE NEWSWIRE) -- The "Postoperative nausea and vomiting (PONV) - Market Insights, Epidemiology, and Market Forecast - 2028" drug pipelines has been added to ResearchAndMarkets ...

The latest Consensus Guidelines for the Management of PONV (CGM-PONV) recommend an assessment of a patient's baseline risk for PONV using a validated risk score based on independent predictors. The ...

Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting (PONV). The data generated demonstrated a statistically significant reduction in the ...

Heron Therapeutics (HRTX) announced the inclusion of APONVIE injectable emulsion in the newly released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting: Executive ...

Barhemsys is a selective dopamine-2 and dopamine-3 receptor antagonist. Acacia Pharma has announced the launch and commercial availability of Barhemsys ® (amisulpride injection). Barhemsys, a ...

U.K.-based specialty pharmaceutical firm Acacia Pharma reported positive data from a fourth pivotal study with its antiemetic drug Baremsis™ (amisulpride injection, or APD421). The firm said it ...

APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 ("NK-1”) antagonist indicated for the prevention of PONV in adults, with a long half-life and quicker ...